X0508 4 2023-10-02 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true Chief Operating Officer true Common Shares 2023-10-02 4 M 0 440752 3.85 A 1036149 D Common Shares 2023-10-02 4 S 0 440752 10.8 D 595397 D Common Shares 2023-10-03 4 M 0 606221 3.85 A 1201618 D Common Shares 2023-10-03 4 S 0 606221 10.25 D 595397 D Common Shares 2023-10-04 4 M 0 153027 3.85 A 748424 D Common Shares 2023-10-05 4 S 0 153027 10.11 D 595397 D Stock Option (Right to Buy) 3.85 2023-10-02 4 M 0 440752 0 D 2032-04-19 Common Shares 440752 13382432 D Stock Option (Right to Buy) 3.85 2023-10-03 4 M 0 606221 0 D 2032-04-19 Common Shares 606221 12776211 D Stock Option (Right to Buy) 3.85 2023-10-04 4 M 0 153027 0 D 2032-04-19 Common Shares 153027 12623184 D The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. The Reporting Person's Rule 10b5-1 trading plan does not include any further sales for this calendar year below a sales price of $14.85. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2023-10-04